• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Syed Mohd Syed Johan Bin

    4/30/25 4:30:31 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Syed Mohd Syed Johan Bin

    (Last) (First) (Middle)
    UNIT A-33A-6, LEVEL 33A TOWER A,
    UOA BANGSAR TOWER

    (Street)
    KUALA LUMPUR N8 59000

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    OPGEN INC [ OPGN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Technology Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Syed Johan Bin Syed Mohd 04/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OPGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    SEC Filings

    See more
    • OpGen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - OPGEN INC (0001293818) (Filer)

      5/29/25 5:20:29 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-Q filed by OpGen Inc.

      NT 10-Q - OPGEN INC (0001293818) (Filer)

      5/16/25 4:39:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form NT 10-K filed by OpGen Inc.

      NT 10-K - OPGEN INC (0001293818) (Filer)

      3/31/25 5:00:19 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

      ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

      5/24/24 4:04:59 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Announced 1-for-10 Reverse Stock Split

      ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

      5/16/24 7:00:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Provides Update on Business Operations and Strategic Opportunities

      ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it entered into an agreement to sell its commercial customer contracts and installed base of Unyvero systems to Camtech Pte Ltd ("Camtech"), a Singaporean family office for $218,000. The transaction follows Camtech's prior acquisition of all of Curetis GmhH's ("Curetis"), the Company's subsidiary, Unyvero assets, rights and businesses, as part of Curetis' insolvency proceedings. In addition, the Company's subsidiary, Ares Genetics GmbH, sold all of its assets, including the ARESdb database and intellectual property portfolio to bioMerieux S.A., as part of Are

      4/29/24 4:05:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Financials

    Live finance-specific insights

    See more
    • OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

      8/10/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

      ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

      8/3/23 7:30:00 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

      Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

      5/15/23 4:15:00 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/10/24 12:32:18 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      10/8/24 6:51:09 PM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright resumed coverage on OpGen with a new price target

      HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

      3/15/21 7:37:07 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/8/21 8:22:12 AM ET
      $OPGN
      Medical Specialities
      Health Care
    • Alliance Global Partners reiterated coverage on OpGen with a new price target

      Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

      3/2/21 10:53:18 AM ET
      $OPGN
      Medical Specialities
      Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by OpGen Inc.

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      8/1/24 5:25:39 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/25/24 5:43:11 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

      SC 13D/A - OPGEN INC (0001293818) (Subject)

      4/8/24 4:05:12 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:32:10 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Syed Mohd Syed Johan Bin

      3 - OPGEN INC (0001293818) (Issuer)

      4/30/25 4:30:31 PM ET
      $OPGN
      Medical Specialities
      Health Care
    • Director Wong Poh Yin Constance was granted 28,571 shares (SEC Form 4)

      4 - OPGEN INC (0001293818) (Issuer)

      12/19/24 4:34:06 PM ET
      $OPGN
      Medical Specialities
      Health Care